aOncobell Program, Bellvitge Biomedical Research Institute (IDIBELL)
bOphthalmology Department, Spanish Ocular Oncology National referal center (CSUR) and Ocular Translational Eye Research Unit, Hospital Universitari de Bellvitge (HUB)-IDIBELL
cDermatology Department, Hospital Universitari de Bellvitge
dPathology Department, Hospital Universitari de Bellvitge
eRadiotherapy Department, Institut Catalá d’Oncologia (ICO), Hospital Duran Reynals
fMedical Oncology, Institut Catalá d’Oncologia (ICO), Hospital Duran Reynals, Barcelona, Spain
Received 17 May 2022 Accepted 6 September 2022
*Àngels Fabra and José M.Caminal contributed equally to the writing of the article.
Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.melanomaresearch.com.
Correspondence to: Àngels Fabra, PhD, Idibell, Oncobell Program, Hospital Duran Reynals. Granvia de l’Hospitalet 199, L’Hospitalet de Llobregat, 08907, Spain, Tel: +34 60 086 5377; e-mail: [email protected]